

ORLADEYO® (berotralstat) capsules

This list does not imply that the products on this chart are interchangeable or have the same efficacy or safety. Please refer to each product's FDA-approved label and indication for further information.

The prices listed below are average wholesale prices (AWPs) as established and made available to the public by a third-party publisher. The price paid by consumers may be higher or lower than the prices listed below. Information about AWP of these drugs is being provided to Vermont prescribers pursuant to Vermont law, to give you information about the relative prices of marketed drugs and other drugs in the same therapeutic class.

The prices listed here do not necessarily reflect price per dosage, price per course of treatment, or the cost effectiveness of all the products listed. For simplicity, only the smallest package sizes available for each product are included.

Price comparison: Marketed product and lowest dosage of other products in same therapeutic class.^a

Marketed product:

ORLADEYO 110 MG CAPSULE	\$1,906.47
-------------------------	------------

Other products:

TAKHZYRO 300 MG/2 ML VIAL SUBCUTANEOUS SOLUTION	NON-PILL PRODUCT
---	------------------

TAKHZYRO 300 MG/2 ML SUBCUTANEOUS SOLUTION PREFILLED SYRINGE	NON-PILL PRODUCT
--	------------------

TAKHZYRO 150 MG/ML SUBCUTANEOUS SOLUTION PREFILLED SYRINGE	NON-PILL PRODUCT
--	------------------

HAEGARDA 2000 IU VIAL SUBCUTANEOUS SOLUTION RECONSTITUTED	NON-PILL PRODUCT
---	------------------

CINRYZE 500 UNIT VIAL INTRAVENOUS SOLUTION RECONSTITUTED	NON-PILL PRODUCT
--	------------------

^aPrices shown are for the lowest dosage of each product. Prices for multi-source products have been averaged. Multiple forms of the same product (eg, tabs and caps) have been considered one product, and the prices have been averaged. Chewable forms of the product are not included.

For additional price comparison information see:

<https://www.biocryst.com/wp-content/uploads/Vermont-AWP-Disclosure-Orladeyo-Long-Form.pdf>

Source: Medi-Span, January 8, 2025